EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk factors and outcome of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia

Seham Hassan, Sonia Ahmed, Nesreen Ali, Abeer Mokhles, Iman Zaky, Hala Reda, Sarah H Youssef, Dina Hammad, Omneya Hassanain, Iman Sidhom

Frontiers in Oncology · 26.06.2025 · 15

DOI: 10.3389/fonc.2025.1606261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 26.06.2025. Verfasst von Seham Hassan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Department, Children's Cancer Hospital Egypt, Cairo, Egypt. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asparaginase-associated pancreatitis (AAP) poses a significant challenge in pediatric patients with acute lymphoblastic leukemia (ALL), with its severity ranging from mild cases to potentially life-threatening conditions.

Aim

To study the incidence, risk factors of AAP, and its impact on outcome in pediatric ALL patients in a large pediatric oncology hospital in a low-and middle-income country. Patient and methods This retrospective study included 1804 pediatric patients newly diagnosed with ALL at a single tertiary care center from June 2012 to December 2017. They were treated with ALL protocol adopted from St Jude total study XV including native E. coli L-asparaginase.

Results

Sixty-three (3.5%) patients experienced AAP. Age ≥10 years at diagnosis, initial white blood cell count (WBC) ≥50x10 9 /L, and standard/high-risk treatment regimen were significantly associated with developing AAP. By multivariate analysis, age ≥10 years and high-dose asparaginase regimens remained significant risk factors for AAP. Mild/moderate AAP was reported in 47 (75%) patients without associated mortality, however, 6/16 (37.5%) patients with severe pancreatitis died. Asparaginase was re-challenged in 39/63 (62%) patients of whom 12 patients (30.8%) experienced recurrent AAP without mortality. Patients who were not re-exposed to asparaginase had a relapse rate of 37.5% compared to 23% for those who were re-challenged. The 5-year event-free-survival (EFS) and cumulative incidence of relapse (CIR) were 63.5% and 24.3%; respectively; for patients with AAP compared to 77% and 14.4% for those without AAP (P=0.01, P=0.02; respectively). However, AAP lost its significant impact when adjusted to other factors including age, WBC, immunophenotype, and ALL risk stratification (EFS: HR1.32; 95%CI, 0.88-1.98; P=0.17 and CIR: HR1.44; 95%CI, 0.86-2.4; P=0 .16).

Conclusion

Older age and high-dose asparaginase regimens are independent risk factors of AAP. The decision to re-challenge asparaginase should be carefully considered balancing the risk of recurrent pancreatitis against the potential risk of leukemic relapse.

Schlagwörter

Stichwörter der Autor:innen

acute lymphoblastic leukemiaasparaginaselow and middle-income countriespancreatitispediatricrisk factors

Autor:innen und Institutionen

  • Pediatric Oncology Department, Children's Cancer Hospital Egypt, Cairo, Egypt.
  • Pediatric Oncology Department, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.
  • Clinical Oncology Department, Beni-Suef University, Egypt and Children's Cancer Hospital Egypt, Cairo, Egypt.
  • Radiology Department, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.
  • Clinical Pathology Department, National Cancer Institute, Cairo University, and Children's Cancer Hospital Egypt, Cairo, Egypt.
  • Department of Pharmaceutical Services, Children's Cancer Hospital Egypt, Cairo, Egypt.

Zitieren

APA

Hassan, S., Ahmed, S., Ali, N., Mokhles, A., Zaky, I., Reda, H., Youssef, S. H., Hammad, D., Hassanain, O., & Sidhom, I. (2025). Risk factors and outcome of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1606261

Vancouver

Hassan S, Ahmed S, Ali N, Mokhles A, Zaky I, Reda H, et al. Risk factors and outcome of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1606261

BibTeX
@article{Hassan2025,
  author = {Hassan, Seham and Ahmed, Sonia and Ali, Nesreen and Mokhles, Abeer and Zaky, Iman and Reda, Hala and Youssef, Sarah H and Hammad, Dina and Hassanain, Omneya and Sidhom, Iman},
  title = {Risk factors and outcome of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1606261}
}
Kostenlos starten →